Prelude Therapeutics Incorporated

NasdaqGS:PRLD Stock Report

Market Cap: US$52.8m

Prelude Therapeutics Management

Management criteria checks 3/4

Prelude Therapeutics' CEO is Kris Vaddi, appointed in Feb 2016, has a tenure of 8.75 years. total yearly compensation is $2.64M, comprised of 21.7% salary and 78.3% bonuses, including company stock and options. directly owns 3.93% of the company’s shares, worth $2.08M. The average tenure of the management team and the board of directors is 2.9 years and 4.5 years respectively.

Key information

Kris Vaddi

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage21.7%
CEO tenure8.8yrs
CEO ownership3.9%
Management average tenure2.9yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Sep 16
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 09
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Feb 03

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Sep 17
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 28
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Jan 28
Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Oct 27
We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Prelude wins FDA clearance to start Phase 1 trial for cancer candidate

Oct 18

Prelude downgraded at Morgan Stanley ahead of key update

Sep 09

We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Jun 28
We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Mar 14
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Dec 14
We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Jul 05
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Feb 16
What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Prelude Therapeutics prices $150M share offering

Jan 07

Prelude Therapeutics readies public offering

Jan 04

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

Dec 25
Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

CEO Compensation Analysis

How has Kris Vaddi's remuneration changed compared to Prelude Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$132m

Jun 30 2024n/an/a

-US$130m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$3mUS$573k

-US$122m

Sep 30 2023n/an/a

-US$117m

Jun 30 2023n/an/a

-US$117m

Mar 31 2023n/an/a

-US$114m

Dec 31 2022US$3mUS$558k

-US$115m

Sep 30 2022n/an/a

-US$120m

Jun 30 2022n/an/a

-US$120m

Mar 31 2022n/an/a

-US$120m

Dec 31 2021US$7mUS$544k

-US$112m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$69m

Dec 31 2020US$12mUS$417k

-US$57m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$2mUS$315k

-US$28m

Compensation vs Market: Kris's total compensation ($USD2.64M) is above average for companies of similar size in the US market ($USD652.28K).

Compensation vs Earnings: Kris's compensation has been consistent with company performance over the past year.


CEO

Kris Vaddi (58 yo)

8.8yrs

Tenure

US$2,641,789

Compensation

Dr. Krishna Vaddi, D.V.M., Ph D., also known as Kris, founded Prelude Therapeutics Incorporated and serves as its Chief Executive Officer and Director from February 2016. He has been its Chief Executive Of...


Leadership Team

NamePositionTenureCompensationOwnership
Krishna Vaddi
Founder8.8yrsUS$2.64m3.93%
$ 2.1m
Edna Huang
President & Chief Medical Officer2.6yrsUS$1.65m0.12%
$ 60.8k
Bryant Lim
Interim CFO1.8yrsUS$1.67m0.0044%
$ 2.3k
Aimee Crombie
Senior VP and Head of Strategic Planning & Operations2.8yrsno datano data
Madhu Pudipeddi
Senior Vice President of Technical Operations3.8yrsno datano data
Peggy Scherle
Chief Scientific Officer6.6yrsUS$1.63m0.33%
$ 173.5k
Lindsey Trickett
Vice President of Investor Relationsno datano datano data
Michele Porreca
Chief People Officer3.4yrsno datano data
Andrew Combs
Executive VP & Chief Chemistry Officer5.6yrsUS$2.63m0.57%
$ 299.6k
Naveen Babbar
Senior Vice President of Translation Medicine2.9yrsno datano data
William Novotny
Senior Vice President of Clinical Development2.2yrsno datano data
Wan-Jen Hong
Senior Vice President of Clinical Development2.1yrsno datano data

2.9yrs

Average Tenure

55yo

Average Age

Experienced Management: PRLD's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Krishna Vaddi
Founder8.8yrsUS$2.64m3.93%
$ 2.1m
Julian Baker
Independent Director3.8yrsUS$140.03k0%
$ 0
Paul Friedman
Independent Chairman of the Board8.3yrsUS$161.03k0.91%
$ 480.1k
Martin Babler
Independent Director3.3yrsUS$134.53k0%
$ 0
David Bonita
Independent Director8.3yrsUS$144.53k0%
$ 0
Mardi Dier
Independent Director4.3yrsUS$147.03k0.018%
$ 9.6k
Victor Sandor
Independent Director4.5yrsUS$131.03k0%
$ 0

4.5yrs

Average Tenure

58yo

Average Age

Experienced Board: PRLD's board of directors are considered experienced (4.5 years average tenure).